Research Progress of SN38 Drug Delivery System in Cancer Treatment
Qing-rui Qi,Huan Tian,Bao-sen Yue,Bing-tao Zhai,Feng Zhao
DOI: https://doi.org/10.2147/ijn.s435407
IF: 7.033
2024-01-27
International Journal of Nanomedicine
Abstract:Qing-rui Qi, 1 Huan Tian, 2 Bao-sen Yue, 2 Bing-tao Zhai, 1 Feng Zhao 2 1 State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), and Shaanxi Key Laboratory of Chinese Medicine Fundamentals and New Drugs Research, and Shaanxi Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Shaanxi University of Chinese Medicine, Xi'an, 712046, People's Republic of China; 2 Xi'an Hospital of Traditional Chinese Medicine, Xi'an, 710021, People's Republic of China Correspondence: Bing-tao Zhai; Feng Zhao, Email ; The active metabolite of irinotecan (CPT-11), 7-ethyl-10-hydroxycamptothecin (SN38), is 100– 1000 times more active than CPT-11 and has shown inhibitory effects on a range of cancer cells, including those from the rectal, small cell lung, breast, esophageal, uterine, and ovarian malignancies. Despite SN38's potent anticancer properties, its hydrophobicity and pH instability have caused substantial side effects and anticancer activity loss, which make it difficult to use in clinical settings. To solve the above problems, the construction of SN38-based drug delivery systems is one of the most feasible methods to improve drug solubility, enhance drug stability, increase drug targeting ability, improve drug bioavailability, enhance therapeutic efficacy and reduce adverse drug reactions. Therefore, based on the targeting mechanism of drug delivery systems, this paper reviews SN38 drug delivery systems, including polymeric micelles, liposomal nanoparticles, polymeric nanoparticles, protein nanoparticles, conjugated drug delivery systems targeted by aptamers and ligands, antibody-drug couplings, magnetic targeting, photosensitive targeting, redox-sensitive and multi-stimulus-responsive drug delivery systems, and co-loaded drug delivery systems. The focus of this review is on nanocarrier-based SN38 drug delivery systems. We hope to provide a reference for the clinical translation and application of novel SN38 medications. Keywords: SN38, drug delivery system, cancer Camptothecin, a pentacyclic alkaloid isolated by Well et al from the Chinese dove plant Camptotheca acuminata in 1966, 1 has drawn considerable interest from academics. More research has revealed that topoisomerase I (Topo I) inhibitors such as camptothecin and its derivatives bind to Topo I to create a CPT-Topo I-DNA ternary complex, which prevents DNA synthesis and ultimately causes cancer cells to die. 2 The first comedogenic derivatives to receive FDA approval were topotecan (TPT) and irinotecan (CPT-11), which are now frequently used as chemotherapeutic medicines. For the treatment of small-cell lung and ovarian cancers, TPT has been licensed as a second-line agent, and CPT-11 has been approved as a first-line agent for the treatment of metastatic colorectal malignancies. 3 However, CPT-11 is an inactive prodrug, which needs to be converted to its active metabolite SN38 by hepatic carboxylesterase activation, and carboxylesterase has inter-individual variability and low activity. Meanwhile, only 2~8% of CPT-11 is converted to SN38 in vivo, 4 which is converted to the water-soluble inactive metabolite SN38 glucuronide (SN38G) in the liver by ureidoside diphosphate glucuronosyltransferase (UGT1A1), and SN38G excreted in the intestine is converted to SN38 by the bacterial enzyme β-Glucosidase (β-Glu). Free SN38 directly affects healthy cells like the intestinal epithelium, which can have negative effects including delayed-onset diarrhea. 5,6 7-Ethyl-10-hydroxycamptothecin (SN38) is the main active metabolite of CPT-11, which has been shown to be effective against a variety of tumor cells, including those from colorectal, small cell lung, lymphoma, breast, esophageal, and uterine cancers, as well as in the treatment of many types of tumors, such as colorectal, small cell lung, and lymphatic carcinoma, breast, esophageal, uterine and ovarian cancers. 7 The biological activity is 100–1000 times more than that of CPT-11 8 and it does not require hepatic carboxylesterase for metabolization, which eliminates the drug's individual variations. However, the relatively high hydrophobicity and instability of SN38 at physiological pH limit its clinical translation. SN38 has a molecular weight of 392.4 g/moL, an ionization constant of pKa of 2.01 and an oil-water partition coefficient of logP of 2.65 at 25°C, and is virtually insoluble in water as well as in most medical solvents and oils, but only in 0.5% dimethyl sulfoxide, formic acid, and acetic acid. So the direct production of liquid formulations are limited. In addition, the E-ring lactone structure of SN38 is subject to reversible PH-dependent hydrolysis, which is shown in ( Figure S1< -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology